Skip to main content
    B

    Bausch Health Companies Inc (BHC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $8.43
    +0.07 (+0.90%)

    Market Cap: $3.13B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bausch Health Companies Inc (BHC) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Bausch Health Companies reported EPS of $1.77, above the $1.08 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +6.53%
    Streak
    3 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$1.39
    Range$1.21 - $1.56
    4 analysts
    Revenue Consensus
    $2.81B
    Range$2.72B - $2.93B
    4 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus$0.79
    Range$0.71 - $0.87
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.82-3.0%
    60d ago$0.82-3.0%
    30d ago$0.82-3.0%
    7d ago$0.82-3.9%
    Current$0.79
    Revenue Consensus
    $2.52B
    Range$2.50B - $2.54B
    2 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 28.7% above the $1.08 reported for the quarter ended Dec 31, 2025.

    BHC's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    BHC Earnings Call

    The latest BHC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BHC beat 30 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $2.94B, up 9.7% from $2.68B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.77$1.08N/A+63.89%Beat+52.6%61 up, 0 downOct 28, 2026$2.94B
    Jun 30, 2026$1.26$0.96$0.93 - $1.20+31.25%Beat+38.5%52 up, 0 downJul 29, 2026$2.85B
    Mar 31, 2026$0.78$0.69$0.48 - $0.87+13.04%Beat+27.9%70 up, 1 downApr 29, 2026$2.52B
    Dec 31, 2025$1.08$1.21$1.13 - $1.39-10.74%Miss-6.9%60 up, 1 downFeb 18, 2026$2.80B
    Sep 30, 2025$1.16$1.06$0.81 - $1.18+9.43%Beat+2.7%52 up, 0 downOct 29, 2025$2.68B
    Jun 30, 2025$0.91$0.94$0.82 - $1.10-3.19%Miss-7.1%51 up, 0 downJul 30, 2025$2.53B
    Mar 31, 2025$0.61$0.85$0.72 - $1.06-28.24%Miss+3.4%51 up, 1 downApr 30, 2025$2.26B
    Dec 31, 2024$1.16$1.13$0.90 - $1.37+2.96%Beat+0.9%62 up, 1 downFeb 19, 2025$2.56B
    Sep 30, 2024$1.13$1.02$0.92 - $1.16+10.78%Beat+9.7%71 up, 1 downOct 30, 2024$2.51B
    Jun 30, 2024$0.98$0.88$0.79 - $1.00+11.36%Beat+21.0%60 up, 1 downAug 1, 2024$2.40B
    Mar 31, 2024$0.59$0.72$0.59 - $0.85-18.06%Miss+11.3%51 up, 0 downMay 2, 2024$2.15B
    Dec 31, 2023$1.15$1.02$0.99 - $1.11+12.75%Beat+11.7%61 up, 1 downFeb 22, 2024$2.41B
    Sep 30, 2023$1.03$0.92$0.82 - $1.02+11.96%Beat+35.5%51 up, 1 downNov 2, 2023$2.24B
    Jun 30, 2023$0.81$0.73$0.64 - $0.85+10.96%Beat+47.3%60 up, 1 downAug 3, 2023$2.17B
    Mar 31, 2023$0.53$0.68$0.63 - $0.84-22.06%Miss-26.4%50 up, 0 downMay 4, 2023$1.94B
    Dec 31, 2022$1.03$0.95$0.73 - $1.11+8.42%Beat-19.5%60 up, 1 downFeb 23, 2023$2.19B
    Sep 30, 2022$0.76$0.78N/A-2.56%Miss-33.9%70 up, 2 downNov 3, 2022$2.05B
    Jun 30, 2022$0.55$0.91$0.79 - $1.00-39.56%Miss-43.3%70 up, 0 downAug 9, 2022$1.97B
    Mar 31, 2022$0.72$1.03N/A-30.10%Miss-29.4%50 up, 1 downMay 10, 2022$1.92B
    Dec 31, 2021$1.28$1.12N/A+14.29%Beat-3.8%71 up, 0 downFeb 23, 2022$2.20B
    Sep 30, 2021$1.15$1.06$1.01 - $1.10+8.49%Beat-12.2%90 up, 1 downNov 2, 2021$2.11B
    Jun 30, 2021$0.97$0.95$0.80 - $1.04+2.11%Beat+110.9%9N/AAug 3, 2021$2.10B
    Mar 31, 2021$1.02$0.95$0.83 - $1.07+7.37%Beat+14.6%10N/AMay 4, 2021$2.03B
    Dec 31, 2020$1.33$1.12$0.88 - $1.38+18.75%Beat+15.7%14N/AFeb 24, 2021N/A
    Sep 30, 2020$1.31$1.04$0.87 - $1.28+25.96%Beat+8.3%15N/ANov 3, 2020$2.14B
    Jun 30, 2020$0.46$0.65$0.41 - $0.86-29.23%Miss-57.0%15N/AAug 6, 2020$1.66B
    Mar 31, 2020$0.89$0.88$0.75 - $0.99+1.14%Beat-13.6%15N/AMay 7, 2020$2.01B
    Dec 31, 2019$1.15$1.13$0.99 - $1.45+1.77%Beat+11.7%15N/AFeb 19, 2020$2.22B
    Sep 30, 2019$1.21$1.09$0.97 - $1.30+11.01%Beat+5.2%15N/ANov 4, 2019$2.21B
    Jun 30, 2019$1.07$1.06$0.94 - $1.14+0.94%Beat+15.1%14N/AAug 6, 2019$2.15B
    Mar 31, 2019$1.03$0.86$0.75 - $0.97+19.77%Beat+17.0%14N/AMay 6, 2019$2.02B
    Dec 31, 2018$1.03$0.84$0.60 - $1.01+22.62%Beat+5.1%13N/AFeb 20, 2019$2.12B
    Sep 30, 2018$1.15$0.86$0.56 - $0.93+33.72%Beat+10.6%13N/ANov 6, 2018$2.14B
    Jun 30, 2018$0.93$0.80N/A+16.25%Beat-11.4%N/AN/AAug 7, 2018$2.13B
    Mar 31, 2018$0.88$0.60N/A+46.67%Beat+12.8%N/AN/AMay 8, 2018$2.00B
    Dec 31, 2017$0.98$0.97N/A+1.03%Beat-22.2%N/AN/AFeb 28, 2018$2.16B
    Sep 30, 2017$1.04$0.89N/A+16.85%Beat-32.9%N/AN/ANov 7, 2017$2.22B
    Jun 30, 2017$1.05$0.96N/A+9.38%Beat-25.0%N/AN/AAug 8, 2017$2.23B
    Mar 31, 2017$0.78$0.82N/A-4.88%Miss-38.6%N/AN/AMay 9, 2017$2.11B
    Dec 31, 2016$1.26$1.20N/A+5.00%Beat-49.6%N/AN/AFeb 28, 2017$2.40B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $3.76, down 2.6% from the year before. It was $5.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$3.76-2.6%
    Dec 31, 2024$3.86+9.7%
    Dec 31, 2023$3.52+15.0%
    Dec 31, 2022$3.06-30.8%
    Dec 31, 2021$4.42+10.8%
    Dec 31, 2020$3.99-10.5%
    Dec 31, 2019$4.46+11.8%
    Dec 31, 2018$3.99+3.6%
    Dec 31, 2017$3.85-29.7%
    Dec 31, 2016$5.48N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,4647
    2026Q2Jun 30, 20265,2258
    2026Q1Mar 31, 20265,9029
    2025Q4Dec 31, 20256,50310
    2025Q3Sep 30, 20255,93811
    2025Q2Jun 30, 20254,9318
    2025Q1Mar 31, 20256,5949
    2024Q4Dec 31, 20246,65210

    2026Q3 Earnings Call

    Opening remarks

    Garen Sarafian Vice President of Investor Relations Good afternoon, and welcome to Bausch Health's third quarter 2026 Earnings Conference Call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas J. Appio, Chief Executive Officer; Jean-Jacques Charhon, Chief Financial Officer; and Jonathan Sadeh, Chief Medical Officer and Head of Research and Development. Before we begin, I would like to remind you that today's presentation contains forward-looking information. Please take a moment to review the forward-looking statements disclaimer at the beginning of the slides accompanying this presentation. It contains important information. Actual results may differ materially from those expressed or implied in these forward-looking statements, and you should not place undue reliance on them. Please also refer to our SEC filings and our filings with the Canadian Securities Administrators for a discussion of certain risk factors that could cause actual results to differ materially from expectations. We use non-GAAP financial measures to help investors better understand our operating performance. These non-GAAP measures may not be comparable to similarly titled measures used by other companies and should be considered in addition to, and not as a substitute for, measures calculated in accordance with GAAP. Reconciliations to our non-GAAP measures are included in the appendix of the slides accompanying this presentation, which are also available on Bausch Health's Investor Relations website. Finally, financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Wednesday, October 28, will focus on Bausch Health excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's results announced this morning. We will refer to year-over-year comparisons with the same period last year unless otherwise noted. With that, I will turn the call over to our CEO, Tom Appio. Tom?

    Thomas J. Appio CEO Thank you, Garen, and thank you to everyone joining us today. Before I discuss our third-quarter results, I want to briefly address my recent appointment as interim CEO of Bausch + Lomb. I am honored and energized to serve as interim CEO. Having spent a good part of my career with the company, I have developed a deep understanding of its business, markets, products, and, most importantly, the exceptional global team that drives its success. Having said that, I want to reiterate that I remain fully committed to Bausch Health and all its stakeholders. I am proud of our 7,000 colleagues around the world and all that we continue to achieve together. Both companies have experienced teams and well-defined operating priorities, allowing us to remain focused on execution across each business.

    Frequently Asked Questions About BHC

    Did BHC beat earnings estimates last quarter?

    Yes. Bausch Health Companies reported EPS of $1.77 for the quarter ended Sep 30, 2026, above the $1.08 estimate, a 63.89% surprise.

    What EPS do analysts expect from BHC next quarter?

    The consensus EPS estimate for Bausch Health Companies for the quarter ending Dec 31, 2026 is $1.39 from 4 analysts, with estimates from $1.21 to $1.56.

    How often does BHC beat earnings estimates?

    Bausch Health Companies beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +9.80%.